



## The effect of Iranian capripoxvirus vaccine strains on neutralizing antibody titer in cattle

Hamed Isapour,<sup>a</sup> Mehdi Sakha,<sup>b</sup> Hamid Reza Varshovi<sup>c</sup>

<sup>a</sup> Resident of large animal internal medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran.

<sup>b</sup> Department of Clinical Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran.

<sup>c</sup> Department of Animal Viral Vaccines, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

### ABSTRACT

Lumpy skin disease (LSD) virus, Goat-poxvirus (GPV), and Sheep-poxvirus (SPV) are members of genus capripoxvirus (CaPV) and have close genetic similarity. The use of CaPV-vaccine strains would be useful to protect the cattle against LSD. This study aimed to compare the neutralizing antibody titer of Iranian heterologous sheep pox and goat pox vaccines against LSD in cattle. A total of 100 calves was vaccinated with Gorgan-GPV and Ramyar-SPV vaccines on separate farms. Neutralizing antibody titer and side effects of vaccines were evaluated at days 14, 28, 45, 90, and 180 post-vaccination. The mean of rectal temperature in SPV was higher than GPV and persisted for up to 3 days. Also during the onset time of fever, ocular and nasal discharge were observed, whereas in the GPV and control group no clinical signs were observed. In each vaccinated group, the first detectable antibody titer was after 14 days and rose to peak at 28-45 days post-vaccination, then it decreased in the following days. Although, the mean of the neutralizing index (NI) titer between GPV and SPV was relatively similar and there was no statistically significant difference ( $p > 0.05$ ) at all days of the experiment, but in GPV the titer appeared slightly higher than SPV and reached to protective level ( $NI \geq 1.5$ ) on day 45 post-vaccination. There was a high antibody titer ( $\text{Log}_{10}^{1.07}$ ) in the day 180 post-vaccination. The results showed that GPV vaccine because of the induction of the protective level of antibody titer, and persisting within a long period for up to 180 day post-vaccination, has a good immunogenic response, so is considered a suitable vaccine to control LSD.

### Keywords

sheep pox virus, goat pox virus, capripox vaccine,  
Neutralizing antibody

### Abbreviations

CaPV: Capripoxvirus

DPV: Day's post vaccination

GGPV: Gorgan-goat pox virus

GPV: Goat pox virus

GVC: GGPV-vaccinated calves

LSD: Lumpy skin disease

NI: Neutralizing index

OIE: The world organization for animal health

RSPV: Ramyar-sheep pox virus

RVC: RSPV-vaccinated calves

RVSRI: Razi vaccine and serum research institute

SNT: Serum neutralization test

SPV: Sheep pox virus

Number of Figures: 1  
Number of Tables: 1  
Number of References: 30  
Pages: 77-82

Lumpy skin disease (LSD) is an infectious disease of cattle caused by a double-stranded DNA virus of the capripoxvirus genus of the *Poxviridae* family [1, 2]. Lumpy skin disease due to the rapid spread and economic importance in cattle has been considered in "list A" of bovine diseases by OIE [3, 4]. Several capripoxvirus (CaPV) vaccine strains are used for the prevention and control of LSD [5-7]. According to many studies, it has been proven that CaPV strains share a major neutralizing site, so that animals are infected with one strain of CaPV family and survived from it, will be resistant to infection with any other strains. Therefore, the use of vaccine strains of CaPV derived from sheep and goats would be useful to protect cattle against LSD [5, 8-10]. In Iran, two live attenuated strains of CaPV are used as vaccines for the control of LSD [11]. These are strains of goat and sheep pox virus that are produced by the Razi Vaccine and Serum Research Institute (RVSRI). After a recent outbreak of LSD in Iran in 2014, an emergency vaccination program with heterologous existing vaccines including GPV and SPV vaccines was carried out in the bovine population of the country [10]. Inadequate protective immunity can cause the outbreak of the disease in cattle populations after exposure to the LSD virus [12, 13]. Therefore, evaluation of immune response characteristics of vaccines against LSDV in field trials is very important to assess the status of the existing vaccine strains and to select the best vaccine strain that effectively protects the cattle population against LSDV.

The study aimed to compare the effect of Iranian capripoxvirus vaccine strains on neutralizing antibody titer in cattle. Accordingly, to the evaluation of humoral immunity, the neutralizing antibody levels of vaccinated calves were monitored weekly, to indicate

the levels of protection expected.


### Monitoring of adverse reactions

The individual rectal temperature value of vaccinated calves was recorded daily and rectal temperatures higher than 40 °C were considered febrile. The fever in GPV-vaccinated calves (GVC), and SPV-vaccinated calves (SVC) was first observed 24 h post-vaccination, continued for up to 72 h post-vaccination, then remained within normal range until the end of the experiment. In general, the mean of fever in SVC was higher than GVC, and persisted for up to 3 days. Also, in 32% of SVC (16 calves), ocular and nasal discharge was observed, whereas in GVC and control group any clinical signs were not observed.

### Neutralizing antibody titers

The serum neutralizing antibody titer of all treated calves were negative before vaccination, but after the vaccination, the neutralizing antibodies were detected. In each vaccinated group, the first detectable neutralizing antibody titer was after 14 days and rose to peak at 28-45 days post-vaccination (dpv). Then it decreased in the following days, while in the control group there was no antibody response. Although, the mean of the neutralizing antibody titer between vaccinated groups at days 14, 28, 45, 90, and 180 post-vaccination were relatively similar, but in GVC was slightly higher than SVC, and in the 90 and 180 dpv it had a higher antibody titer ( $\text{Log}_{10}^{1.07}$ ) than SVC. As shown in Fig. 1, the mean neutralization index was higher for SVC on days 14 and 28 post-vaccination and for GVC on days 45, 90, and 180 post-vaccination.

### Comparison of the seroconversion status of vaccinated calves



**Figure 1.** Comparison of the neutralizing antibody titer of vaccinated calves in response to sheep pox virus (SPV) and goat pox virus (GPV) vaccines on different days post-vaccination.

**Table 1.**

Generalized estimating equations test results in evaluating the effect of time and vaccine type and their interactions on altering the antibody titer

Variables	Parameter	B	95% confidence interval for B	p-value
Vaccine	SPV	-0.26	-0.56 to 0.04	0.085
	GPV (reference)	.	.	.
Time	Day 180	0.04	-0.21 to 0.29	0.75
	Day 90	0.06	-0.12 to 0.24	0.51
	Day 45	0.52	0.29 to 0.75	<0.001
	Day 28	0.30	0.11 to 0.49	0.002
	Day 14 (reference)	.	.	.
Vaccine*Time	SPV*Day 180	-0.56	-0.89 to -0.24	0.001
	SPV*Day 90	-0.50	-0.82 to -0.18	0.002
	SPV*Day 45	-0.40	-0.72 to -0.08	0.015
	SPV*Day 28	-0.18	-0.44 to 0.08	0.17
	SPV*Day 14	.	.	.

According to the obtained results, the effect of “vaccines” (two Iranian capripoxvirus vaccines) in immune response stimulation and antibody production was not significantly different and the mean of antibody titer in each vaccinated group was similar ( $p = 0.59$ ,  $DF = 1$ , Wald's *Chi-Square* = 0.29). But, the effect of “time” in antibody production was significant, so that the mean antibody titer in each vaccinated group were statistically significant different in five measurement periods ( $p < 0.001$ ,  $DF = 4$ , Wald's *Chi-Square* = 65.16).

Also, the interactive effects of “time” and “vaccines” type on immune response were significant, and the mean antibody titer between the two types of the vaccines did not remain constant over time ( $p = 0.018$ ,  $DF = 4$ , Wald's *Chi-Square* = 11.94). Table 1 shows the details of the generalized estimating equations statistical parameters. In this table, the B value shows the difference of mean antibody titer of each vaccinated group relative to the reference group.

In evaluating the effect of the vaccine type on antibody production, the  $B = -0.26$  value was obtained for SPV, and indicating that the mean antibody titer in SPV was about 0.26 units less than GPV, and this difference was not significant. In interpreting the effect of time on antibody production, the 14th-day post-vaccination was considered as reference day, and the mean antibody titer of the other days was compared to the 14th day.

The mean antibody titer on days 180 ( $p = 0.75$ ,  $B = 0.04$ ) and 90 ( $p = 0.51$ ,  $B = 0.06$ ) in comparison to day 14 (reference day) were not significantly different, but on day 45 ( $p < 0.001$ ,  $B = 0.52$ ), and 28 ( $p = 0.002$ ,  $B = 0.30$ ) this difference was significant. In evaluating the interaction between the two variables; time and vaccine type, the mean antibody titer in SPV was 0.56 units less than of GPV on day 180 (compared to day 14), and this difference was significant ( $B = -0.56$ ,  $p < 0.001$ ). Also, on days 90 and 45, these differences were -0.50 and -0.40 significant. But, on day 28, the mean antibody titer of the two vaccines was not significantly different ( $B = -0.18$ ,  $p = 0.17$ ).

Because of reasonable prices, vaccination has been considered as a practical and effective method to control LSD [4-6]. To prevent and control lumpy skin disease, several capripoxvirus vaccine strains are currently used [14], and despite regular LSD vaccination of cattle, the cases of vaccine failure and re-occurrence of the disease have been reported [15]. However, little information about the immune dynamics and vaccine-cytokines response to LSD is available. In this study, Gorgan-GPV and Ramyar-SPV vaccine-induced immune responses were measured by neutralization antibody titer, because it is a critical parameter in immune response and can be related to the durability of protection.

Clinical examination of both SVC and GVC was performed daily, and in SVC, mild local reactions

and mild swelling were appeared in the site of vaccine injection, as in the previous studies has been shown [3, 10, 16-18]. While in GVC the local reaction at the vaccination site was lower than SVC [7, 10, 19, 20]. According to the incubation period of the disease, as well as reports of disease in this area, it is likely that SVC was in the incubation period and then showed symptoms following the vaccine injection [7, 21]. In many studies, the effective and protective immune system against LSD and other capripoxviruses is the cellular immune response, although both cellular and humoral immunity play a role in regulating of immune responses [22]. For example, Norian et al [10] and Barman et al [23] showed that not only the cellular immunity but the humoral immunity actively protect the cattle against the capripoxvirus disease.

In our study, the neutralizing antibody titer was detected in both groups of vaccinated calves. The vaccinated calves were able to produce antibodies before day 14 post-vaccination. Similarly, in many research studies, it has been indicated that the vaccinated cattle produce neutralizing antibodies before day 7 post-vaccination [20, 21].

The mean of NI antibody titer of two vaccine strains was increased on each day of follow-up and reached the high value at day 45 and decreased until the follow-up ends at day 180. There is accumulated evidence that the capripoxviruses (LSD, goat, and sheep pox viruses) are genetically related as well as their induced antibodies cross-react one another [4, 24]. Accordingly, though our viral strain vaccines were derived from sheep pox (Ramyar strain) and goat pox (Gorgan strain), a significant difference was not observed in antibody induction among the two viral strains used for our experiment across the study time. Between the two vaccinated groups, the seroconversion rates were relatively higher in GPV compare to SPV. The probable and known variables which influence the immune response to capripoxvirus vaccines include differences in virus strain, the dosage of the vaccine, or a difference in the percentages of exotic germplasm composition. The result of this study showed that all calves were able to produce antibodies in response to vaccine strains and reached to protective level at 28 and 45 day post-vaccination [4, 10, 24-26].

### **Executive Limitations**

There were two executive limitations in this study: First, due to the inability to provide the necessary biosecurity, as well as the lack of funding, we were unable to perform the challenge of LSD virus in the vaccinated cattle by the capripoxvirus. While for approval of the protective effect of CaPV vaccines against LSD virus, we need to expose the calves with

LSD virus. But since the LSD virus was on the list A of OIE protocol, this exposure was impossible. Second, the stimulation of immune systems and increases of neutralizing antibody titer may be due to vaccine antigens or the presence of other antigens in the animal's environment. So, the experiment was not performed in the antigen-free area.

Based on the above study we concluded that the Gorgan-GPV and Ramyar-SPV heterologous vaccines stimulated the humoral immune response against LSDV, and induced comparable SNT antibody response after vaccination. Both vaccines induced neutralization antibodies before 14 days, increased regularly thereafter, reached the peak at day 45, and then decreased with a gentle slope until the follow-up ends at day 180 post-vaccination. It seems that the GPV vaccine due to inducing a high level of neutralizing antibody titer against LSD virus, and longer shelf life, can be a suitable vaccine to control the disease in the field.

### **Study Area and Study Population**

This study was conducted in the Zanjan province of Iran. 100 Holstein breed calves with approximately 5-6 months of age were selected from several dairy farms. The calves on each farm were divided into two groups; vaccinated calves as a treated group and unvaccinated calves as a vaccine control group.

### **Types of Vaccine**

The two types of vaccine strains used were Ramyar-Sheep pox virus (SPV) and Gorgan-goat pox virus (GPV), produced by RVSRI of Iran. These vaccines were live attenuated, lyophilized and one dose of each vaccine for goat and sheep contained  $10^{3.2}$  TCID<sub>50</sub>/ml of the virus. A ten-fold dose of vaccines was prepared according to the manufacturer's instructions for emergency use against LSD in cattle [10, 27].

### **Vaccination**

In the vaccination trials, treated groups in each farm were vaccinated with GPV or SPV vaccines separately, and the control groups received PBS alone. The calves were received 5 ml volume of vaccine through subcutaneous, according to the manufacturer's instructions. All immunized calves were daily examined to the appearance of adverse reactions and clinical signs for 180 days following vaccination.

### **Sample collection**

Blood samples were collected regularly at days 0 (before vaccinations), 14, 28, 45, 90, and 180 post-vaccinations. The collected samples were transported to the animal viral vaccine department of RVSRI institute and allowed to clot for 16-24 hrs at room temperature and then the sera sam-



ples were transferred to cryovials under a laminar airflow hood in order to avoid contamination and the serum was kept at -20°C temperature until processed.

### Virus preparation

The GPV- and SPV-vaccine strains and LSDV were obtained from RVSRI and were used to make a master stock of the virus, and also, to eliminate a potential source of variability, a single batch of the virus was used. Virus cultivation was carried out according to the standard protocol of the department of animal viral vaccines of RVSRI following OIE manual [4, 27], and the titer of stock prepared virus, calculated by Reed & Munch method [28].

### Serum Neutralizing Test

In OIE, the serum neutralizing test (SNT) is the gold standard method to detect neutralizing antibodies against capripoxviruses [4, 29, 30]. Therefore the evaluation of the humoral immune responses of all samples was done by this method. The level of neutralizing antibodies index was measured in a micro-neutralization assay in duplicate, according to the standard protocol of RVSRI institute following the OIE manual [4]. Results were read on day seven for the neutralization index. The neutralization titer was recorded as the reciprocal of the initial dilution of serum which caused suppression of cytopathic effect. The neutralization index (NI) was calculated following the method of Reed and Munch [20].

### Statistical analysis

For evaluation of the effects of vaccine type and time (as independent variables) on antibody titer changes (as dependent variable), and because of abnormal distribution of antibody titer and time interval differences, the generalized estimating equations method (GEE) was used. A *p*-value of less than 0.05 was considered significant.

### Authors' Contributions

Conceived and designed the experiments: MS and HRV. Performed the experiments: HI, HRV, and MS. Analyzed the data: HI and HRV. Research space and equipment, reagents/materials/analysis tools: HI and HRV.

### Acknowledgments

This work was financially supported by the Faculty of Veterinary Medicine, Science and Research branch of Tehran, Islamic Azad University.

### Competing Interests

The authors declare no conflict of interest.

### References

- OIE. Manual of Diagnostic tests and vaccines for terrestrial animals. paris: World Organization for Animal Health; 2004. p. 1-17.
- Murphy F, Gibbs E, Horzinek M, Studdert M. Veterinary Virology. 3rd. USA: Academic Press; 1999. p. 277-91.
- Carn VM. Control of capripoxvirus infections. *Vaccine*. 1993;11(13):1275-9.
- OIE. Lumpy skin diseases; Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. paris: World Organization for Animal Health; 2010. p. 1-13.
- Kitching RP. Vaccines for lumpy skin disease, sheep pox and goat pox. *Dev Biol (Basel)*. 2003;114:161-7.
- Carn VM, Kitching RP. The clinical response of cattle experimentally infected with lumpy skin disease (Neethling) virus. *Arch Virol*. 1995;140(3):503-13.
- Gari G, Abie G, Gizaw D, Wubete A, Kidane M, Asgedom H, et al. Evaluation of the safety, immunogenicity and efficacy of three capripoxvirus vaccine strains against lumpy skin disease virus. *Vaccine*. 2015;33(28):3256-61.
- Kitching RP, Hammond JM, Taylor WP. A single vaccine for the control of capripox infection in sheep and goats. *Res Vet Sci*. 1987;42(1):53-60.
- Davies FG, Otema C. Relationships of capripox viruses found in Kenya with two Middle Eastern strains and some orthopox viruses. *Res Vet Sci*. 1981;31(2):253-5.
- Norian R, Ahangran NA, Varshovi H, Azadmehr A. Comparative efficacy of two heterologous capripox vaccines to control lumpy skin disease in cattle. *Bulg J Vet Med*. 2019;22(2).
- Varshovi H, Ghazanfari K, Aghaeipour K, Pourbakhsh S, Shoushtari A, Aghaebrahimian M. Capripoxvirus identification by PCR based on P32 gene. *Arch Razi Inst*. 2009;64(1):19-25.
- Tuppurainen ES, Oura CA. Review: lumpy skin disease: an emerging threat to Europe, the Middle East and Asia. *Transbound Emerg Dis*. 2012;59(1):40-8.
- Brenner J, Bellaiche M, Gross E, Elad D, Oved Z, Haimovitz M, et al. Appearance of skin lesions in cattle populations vaccinated against lumpy skin disease: statutory challenge. *Vaccine*. 2009;27(10):1500-3.
- OIE. Lumpy skin Disease; In Manual of standards chapter. World Organization for Animal Health; 2000. p. 200-17.
- Gari G, Bonnet P, Roger F, Waret-Szkuta A. Epidemiological aspects and financial impact of lumpy skin disease in Ethiopia. *Prev Vet Med*. 2011;102(4):274-83.

16. Coetzer JAW. Lumpy skin disease; Infectious Diseases of Livestock. Oxford University Press; 2004.
17. OIE. Manual of recommended diagnostic techniques and requirements for biological products. World Organization for Animal Health: Rue de Prony; 1992. p. 1-5.
18. Diallo A, Viljoen GJ. Genus capripoxvirus. Poxviruses: Springer; 2007. p. 167-81.
19. Norian R, Afzal Ahangaran N, Azadmehr A. Evaluation of Humoral and Cell-mediated Immunity of Two Capripoxvirus Vaccine Strains against Lumpy Skin Disease Virus. Iran J Virol. 2016;10(4):1-11.
20. Varshovi HR, Norian R, Azadmehr A, Ahangaran NA. Immune response characteristics of Capri pox virus vaccines following emergency vaccination of cattle against lumpy skin disease virus. Iran J Vet Sci Technol. 2018;9(2):33-40.
21. Tilahun Z, Berecha B, Simenew K, Reta D. Towards Effective Vaccine Production: A Controlled Field Trial on the Immunological Response of Three Lumpy Skin Disease Vaccine Strains in Dairy Farms. Academic J Animal Dis. 2014;3(3):17-26.
22. Kitching RPaH, J.M. . Poxvirus infection and immunity. In: P.J. RIMaD, editor. Encyclopaedia of Immunology 3. Academic press, London1992. p. 1261-4.
23. Barman D, Chatterjee A, Guha C, Biswas U, Sarkar J, Roy TK, et al. Estimation of post-vaccination antibody titre against goat pox and determination of protective antibody titre. Small Rumin Res. 2010;93(2):76-8.
24. Varshovi H, Norian R, Azadmehr A, Ahangaran N. Immune response characteristics of Capri pox virus vaccines following emergency vaccination of cattle against lumpy skin disease virus. Iran J Vet Sci Technol. 2017;9(2):33-40.
25. Khafagy HA, Saad MA, Abdelwahab MG, Mustafa AM. Preparation and field evaluation of live attenuated sheep pox vaccine for protection of calves against lumpy skin disease. Benha Vet Med J. 2016;31(2):1-7.
26. Mohamed G.Abdelwahab HAK, Abdelmoneim M. Moustafa, Mohamed A. Saad. Evaluation of Humoral and Cell-mediated Immunity of Lumpy Skin Disease Vaccine Prepared from Local strain calves and Its Related to Maternal Immunity. J Ame Sci. 2016;21(10).
27. Varshovi HR, Keyvanfar H, Aghaiypour K, Pourbakhsh SA, Shooshtari AH, Aghaebrahimian M. Capripoxvirus identification by PCR based on P32 gene Arch Razi Inst. 2009;64(No.1):19-25.
28. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493-7.
29. Babiuk S, Bowden TR, Boyle DB, Wallace DB, Kitching RP. Capripoxviruses: An Emerging Worldwide Threat to Sheep, Goats and Cattle. Transbound Emerg Dis. 2008;55(7):263-72.
30. Gari G, Biteau-Coroller F, LeGoff C, Caufour P, Roger F. Evaluation of indirect fluorescent antibody test (IFAT) for the diagnosis and screening of lumpy skin disease using Bayesian method. Vet Microbiol. 2008;129(3-4):269-80.

**COPYRIGHTS**

©2021 The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

**How to cite this article**

Isapour H, Sakha M, Varshovi HR (2020). The effect of Iranian capripoxvirus vaccine strains on neutralizing antibody titer in cattle. Iran J Vet Sci Technol. 12(2):77-82.  
 DOI: <https://doi.org/10.22067/veterinary.v12i2.84928>  
 URL: [https://ijvst.um.ac.ir/article\\_31044.html](https://ijvst.um.ac.ir/article_31044.html)

## تأثیر سویه های ایرانی واکسن های کاپری پاکس ویروس بروی تیترا آنتی بادی خنثی کننده در گاو

حامد عیسی پور<sup>۱</sup>، مهدی سخا<sup>۲\*</sup>، حمید رضا ورشوی<sup>۳</sup>

<sup>۱</sup>رزیدنت بیماریهای دام بزرگ، دانشگاه آزاد اسلامی، واحد علوم و تحقیقات، تهران، ایران.  
<sup>۲</sup>گروه علوم بالینی، دانشکده دامپزشکی، دانشگاه آزاد اسلامی، واحد علوم و تحقیقات، تهران، ایران.  
<sup>۳</sup>گروه واکسن های ویروسی دام، موسسه تحقیقاتی واکسن و سرم سازی رازی، سازمان تحقیقات، آموزش و ترویج کشاورزی، کرج، ایران.

### چکیده

ویروس بیماری لمپی اسکین، آبله بزی و آبله گوسفندی از اعضاء جنس کاپری پاکس ویروس ها است. استفاده از واکسن های کاپری پاکس ویروس می تواند در محافظت گاوها در برابر بیماری لمپی اسکین (LSD) کمک کند. هدف از این مطالعه مقایسه تیترا آنتی بادی واکسن های هترو لوگ آبله بزی و گوسفندی در برابر بیماری LSD در گاو است. ۱۰۰ گوساله توسط واکسن های آبله بزی (GPV) و آبله گوسفندی (SPV) در فارم های جداگانه واکسینه شدند. تیترا آنتی بادی واکسن در روزهای ۱۴، ۲۸، ۴۵، ۹۰ و ۱۸۰ بعد از واکسیناسیون بررسی شد. میانگین دمای مقعد گوساله های واکسینه شده با GPV نسبت با گوساله های واکسینه شده با SPV نه تنها بالاتر بود بلکه ترشحات چشمی و آبریزش از بینی در زمان تب نیز مشاهده شد در حالیکه در گوساله های واکسینه شده با GPV هیچ علائم بالینی دیده نشد. در گروه های واکسینه اولین تیترا آنتی بادی در روز ۱۴ مشاهده شد و در روز ۲۴ الی ۴۵ بعد از واکسیناسیون به بالاترین میزان خود رسید و سپس در روزهای بعد کاهش یافت. با وجودیکه میانگین تیترا آنتی بادی در هر یک از گروه های واکسینه در روزهای بعد از واکسیناسیون تقزیباً یکسان بود و از نظر آماری اختلاف معنی داری بین آنها مشاهده نشد. اما در گوساله های واکسینه شده با GPV این میزان در روز ۴۵ به سطح محافظت کنندگی خود رسیده بود و در روز ۱۸۰ نیز دارای تیترا بالاتر از SPV داشت. نتایج نشان داد که GPV به جهت القاء بهتر پاسخ ایمنی و ماندگاری بیشتر آنتی بادی در ماه های متوالی بعد از واکسیناسیون، از خاصیت ایمنی زایی بهتری برخوردار بوده و می توان بعنوان واکسن مناسب در برابر LSD بهره برد.

### واژگان کلیدی

آبله بزی، آبله گوسفندی، کاپری پاکس واکسن، آنتی بادی خنثی کننده